Get the Stockscreener App
13.81
3.14%
0.42
After Hours:
13.82
0.010
+0.07%
Immunic Inc stock is traded at $13.81, with a volume of 114.73K.
It is up +3.14% in the last 24 hours and down -9.74% over the past month.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
See More
Previous Close:
$13.39
Open:
$13.36
24h Volume:
114.73K
Relative Volume:
0.48
Market Cap:
$188.11M
Revenue:
-
Net Income/Loss:
$-104.29M
P/E Ratio:
-2.2891
EPS:
-6.0329
Net Cash Flow:
$-81.45M
1W Performance:
-7.93%
1M Performance:
-9.74%
6M Performance:
+121.95%
1Y Performance:
+23.30%
1-Day Range:
$13.18
$14.19
1-Week Range:
$13.18
$15.40
52-Week Range:
$5.062
$15.84
Immunic Inc Stock (IMUX) Company Profile
Name
Immunic Inc
Sector
Industry
Phone
(332) 255-9818
Address
1200 AVENUE OF THE AMERICAS, NEW YORK
Compare IMUX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMUX
Immunic Inc
|
13.81 | 182.39M | 0 | -104.29M | -81.45M | -6.0329 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Immunic Inc Stock (IMUX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-26 | Initiated | Stifel | Buy |
| Apr-15-26 | Downgrade | D. Boral Capital | Buy → Hold |
| Mar-24-26 | Initiated | Guggenheim | Buy |
| Nov-07-25 | Initiated | Roth Capital | Buy |
| Sep-29-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-25-25 | Initiated | William Blair | Outperform |
| Nov-25-24 | Initiated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-27-24 | Initiated | B. Riley Securities | Buy |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Apr-15-21 | Initiated | Aegis Capital | Buy |
| Mar-24-21 | Initiated | JMP Securities | Mkt Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Aug-07-20 | Resumed | ROTH Capital | Buy |
| Jul-20-20 | Initiated | BMO Capital Markets | Outperform |
| Jun-05-20 | Initiated | Wedbush | Outperform |
| May-11-20 | Initiated | H.C. Wainwright | Buy |
| Mar-25-20 | Initiated | ROTH Capital | Buy |
| Jul-11-19 | Initiated | Chardan Capital Markets | Buy |
View All
Immunic Inc Stock (IMUX) Latest News
Immunic Inc (IMUX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immunic Inc (IMUX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IMUX|Immunic Inc|Price:13.390|Chg%:-0.890 - TradingKey
TradingKey - TradingKey
Why Did IMUX Stock Surge 33% Pre-Market Today? - Stocktwits
Immunic, Inc. Revenue Breakdown – NASDAQ:IMUX - TradingView
Immunic Inc. (IMUX) Edges Higher Amid Steady Trading: Key Levels to WatchBlock Trade Flow - dars.gov.et
Immunic lines up three July investor events in Boston and SF - Stock Titan
abrdn discloses 6.05% Immunic (IMUX) stake held for clients - Stock Titan
Immunic posts updated corporate presentation under Regulation FD - TradingView
Immunic (NASDAQ: IMUX) releases new presentation on pipeline and plans - Stock Titan
Immunic (IMUX) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Immunic stock trades steadily as pipeline and Nasdaq listing shape investor focus - Ad-hoc-news.de
Immunic announces participation in July investor conferences - Proactive financial news
Immunic to Participate in Investor Conferences in July - Investing News Network
EQS-News: Immunic to Participate in Investor Conferences in Julyboerse.de - boerse.de
Immunic Names CEO Erik Lundgren to Board - The Globe and Mail
Form 4 Immunic Inc For: 7 July By Investing.com - Investing.com Nigeria
Immunic director granted options for 25,370 shares | IMUX Insider Trading - Stock Titan
IMMUNIC (IMUX) director Barclay Phillips awarded 25,370 stock options as equity pay - Stock Titan
IMMUNIC (IMUX) director receives 25,370 stock options at $14.80 strike price - Stock Titan
Immunic (IMUX) director Jon Congleton granted 25,370 stock options at $14.80 - Stock Titan
Immunic, Inc. Files Form 8-K Announcing Key Company Details and Executive Update (June 29, 2026) - Minichart
Immunic (IMUX) CEO Erik Lundgren appointed to Board as Tamar Howson retires - Stock Titan
Immunic, Inc. Announces Board and Committee Changes - marketscreener.com
IMUXImmunic Inc Options - Finviz
IMUX Should I Buy - Intellectia AI
Form 4 Immunic Inc For: 29 June By Investing.com - Investing.com Australia
Immunic (IMUX) director Jon Congleton awarded 50,740 stock options at $10.90 - Stock Titan
Immunic (IMUX) director receives 25,370 fully vested options - Stock Titan
Immunic (IMUX) director receives grant of 25,370 fully vested options - Stock Titan
Immunic (NASDAQ: IMUX) director receives 25,370 stock options grant - Stock Titan
Immunic (IMUX) director Neermann receives fully vested options on 25,370 shares - Stock Titan
IMMUNIC (IMUX) director Barclay Phillips receives 25,370 fully vested stock options - Stock Titan
IMMUNIC (IMUX) President and COO receives 253,000-share stock option grant - Stock Titan
IMMUNIC (IMUX) CFO awarded stock options for 120,000 common shares - Stock Titan
IMMUNIC (IMUX) director receives 445,000 stock options at $11.60 exercise price - Stock Titan
[Form 4] IMMUNIC, INC. Insider Trading Activity - Stock Titan
Immunic (IMUX) investors boost equity pool and reelect directors at 2026 meeting - Stock Titan
Immunic, Inc.(NasdaqCM: IMUX) added to Russell Microcap Value Benchmark Index - marketscreener.com
Immunic, Inc.(NasdaqCM: IMUX) added to Russell 3000E Value Benchmark - marketscreener.com
Price to earnings forward of Immunic, Inc. – NASDAQ:IMUX - TradingView
Price to earnings forward of Immunic, Inc. – BOATS:IMUX - TradingView
Immunic tests Nurr1 to push beyond MS’s inflammation ceiling - biocentury.com
IMUX News | IMMUNIC INC (NASDAQ:IMUX) - ChartMill
IMUX Stock Price, Quote & Chart - ChartMill
Enterprise value to revenue forward of Immunic, Inc. – MUN:10V - TradingView
Price to book forward of Immunic, Inc. – MUN:10V - TradingView
IMUX Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Immunic, Inc. – NASDAQ:IMUX - TradingView
Price to sales forward of Immunic, Inc. – NASDAQ:IMUX - TradingView
Immunic Inc Stock (IMUX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):